NasdaqGS:STOKBiotechs
Will Stoke’s New Waltham Headquarters for Zorevunersen Commercialization Shift Stoke Therapeutics' (STOK) Narrative?
In January 2026, Stoke Therapeutics entered into a long-term lease for a new 98,500 square-foot headquarters and laboratory at 245 Fifth Avenue in Waltham, Massachusetts, with aggregate estimated base rent of about US$85.5 million through March 31, 2038.
This expanded facility, backed by a US$3 million security deposit, is intended to support Stoke’s preparations to commercialize its potential Dravet syndrome medicine, zorevunersen, and broaden research based on its proprietary...